Banafshé Larijani

Prof. Banafshé Larijani

Centre for Therapeutic Innovation, University of Bath, Bath, Bath and North East Somerset, UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2007 in Science
Verified
Journal Article
Closed access
PDF file
MVMaria K. Vartiainen
Maria K. Vartiainen
SGSebastian Guettler
Sebastian Guettler
BLBanafshé Larijani
Banafshé Larijani
RTRichard Treisman
Richard Treisman
Actin, which is best known as a cytoskeletal component, also participates in the control of gene expression. We report a function of nuclear actin in the regulation of MAL, a coactivator of the transcription factor serum response factor (SRF). MAL, which binds monomeric actin, is cytoplasmic in many cells but accumulates in the nucleus upon serum-induced actin polymerization. MAL rapidly shuttles between cytoplasm and nucleus in unstimulated cells. Serum stimulation effectively blocks MAL nuclear export, which requires MAL-actin interaction. Nuclear MAL binds SRF target genes but remains inactive unless actin binding is disrupted. Fluorescence resonance energy transfer analysis demonstrates that the MAL-actin interaction responds to extracellular signals. Serum-induced signaling is thus communicated to nuclear actin to control a transcriptional regulator.

31 January 2017 in Nature Methods
Verified
Journal Article
Closed access
PPPerrine Paul-Gilloteaux
Perrine Paul-Gilloteaux
XHXavier Heiligenstein
Xavier Heiligenstein
MBMartin Belle
Martin Belle
MDMarie-Charlotte Domart
Marie-Charlotte Domart
BLBanafshé Larijani
Banafshé Larijani
JSJean Salamero
Jean Salamero

20 January 2009 in PLOS Biology
Verified
Journal Article
Open access
PDF file
Veronique CallejaVeronique Calleja
Veronique Calleja
MLMichel Laguerre
Michel Laguerre
PPPeter J Parker
Peter J Parker
BLBanafshé Larijani
Banafshé Larijani
Protein kinase B (PKB/Akt) belongs to the AGC superfamily of related serine/threonine protein kinases. It is a key regulator downstream of various growth factors and hormones and is involved in malignant transformation and chemo-resistance. Full-length PKB protein has not been crystallised, thus studying the molecular mechanisms that are involved in its regulation in relation to its structure have not been simple. Recently, the dynamics between the inactive and active conformer at the molecular level have been described. The maintenance of PKB's inactive state via the interaction of the PH and kinase domains prevents its activation loop to be phosphorylated by its upstream activator, phosphoinositide-dependent protein kinase-1 (PDK1). By using a multidisciplinary approach including molecular modelling, classical biochemical assays, and Förster resonance energy transfer (FRET)/two-photon fluorescence lifetime imaging microscopy (FLIM), a detailed model depicting the interaction between the different domains of PKB in its inactive conformation was demonstrated. These findings in turn clarified the molecular mechanism of PKB inhibition by AKT inhibitor VIII (a specific allosteric inhibitor) and illustrated at the molecular level its selectivity towards different PKB isoforms. Furthermore, these findings allude to the possible function of the C-terminus in sustaining the inactive conformer of PKB. This study presents essential insights into the quaternary structure of PKB in its inactive conformation. An understanding of PKB structure in relation to its function is critical for elucidating its mode of activation and discovering how to modulate its activity. The molecular mechanism of inhibition of PKB activation by the specific drug AKT inhibitor VIII has critical implications for determining the mechanism of inhibition of other allosteric inhibitors and for opening up opportunities for the design of new generations of modulator drugs. A critical protein in cell-signalling pathways, called protein kinase B, regulates many aspects of cell biology from metabolism to proliferation and survival, by modifying other proteins with the addition of a phosphate group. Hence, deregulation of its activity has acute consequences on cell function. Increased activity of a tumour-promoting form of protein kinase B or of upstream regulatory proteins has been observed in tumours, while impaired protein kinase B function has been linked to diabetes. Therefore, understanding the molecular mechanism of protein kinase B activation will help reveal how its activity might be regulated to limit disease progression. Toward this end, we studied how protein kinase B structure relates to its function, to identify molecular mechanisms regulating its kinase activity, modifying its cellular localization, and altering its binding to other proteins. By determining the spatial organization of different regions of the protein in inactive protein kinase B, we discovered a cavity at the interface of two distinct functional regions of the inactive form. We also localized the C-terminal end of the protein to the apex of the cavity, suggesting a role of this domain in regulating the inactive form of the protein. This represents a novel example of negative regulation by inhibition across these different regions of the protein. From these findings, we elucidated the mechanism of action of a highly specific protein kinase B inhibitor, AKT inhibitor VIII. We determined that simultaneous binding of the inhibitor to the two different functional regions, through the cavity, “locks” protein kinase B in an inactive conformation and prevents regulatory proteins from accessing the C-terminal domain.

3 April 2007 in PLOS Biology
Verified
Journal Article
Open access
PDF file
Veronique CallejaVeronique Calleja
Veronique Calleja
DADamien Alcor
Damien Alcor
MLMichel Laguerre
Michel Laguerre
Jongsun ParkJongsun Park
Jongsun Park
BVBorivoj Vojnovic
Borivoj Vojnovic
BLBanafshé Larijani
Banafshé Larijani
Protein kinase B (PKB/Akt) is a pivotal regulator of diverse metabolic, phenotypic, and antiapoptotic cellular controls and has been shown to be a key player in cancer progression. Here, using fluorescent reporters, we shown in cells that, contrary to in vitro analyses, 3-phosphoinositide–dependent protein kinase 1 (PDK1) is complexed to its substrate, PKB. The use of Förster resonance energy transfer detected by both frequency domain and two-photon time domain fluorescence lifetime imaging microscopy has lead to novel in vivo findings. The preactivation complex of PKB and PDK1 is maintained in an inactive state through a PKB intramolecular interaction between its pleckstrin homology (PH) and kinase domains, in a “PH-in” conformer. This domain–domain interaction prevents the PKB activation loop from being phosphorylated by PDK1. The interactive regions for this intramolecular PKB interaction were predicted through molecular modeling and tested through mutagenesis, supporting the derived model. Physiologically, agonist-induced phosphorylation of PKB by PDK1 occurs coincident to plasma membrane recruitment, and we further shown here that this process is associated with a conformational change in PKB at the membrane, producing a “PH-out” conformer and enabling PDK1 access the activation loop. The active, phosphorylated, “PH-out” conformer can dissociate from the membrane and retain this conformation to phosphorylate substrates distal to the membrane. These in vivo studies provide a new model for the mechanism of activation of PKB. This study takes a crucial widely studied regulator (physiology and pathology) and addresses the fundamental question of the dynamic in vivo behaviour of PKB with a detailed molecular mechanism. This has important implications not only in extending our understanding of this oncogenic protein kinase but also in opening up distinct opportunities for therapeutic intervention. Regulation of intracellular signaling depends on the precise operation of molecular switches such as kinases and phosphatases. Disruption of their activities leads to inappropriate cellular proliferation, growth, and survival. Protein kinase B (PKB) is a critical kinase that regulates events downstream of growth factor receptors. It is also involved in human cancer, where its overexpression induces malignant transformation. We studied the molecular mechanisms of PKB's interaction with its upstream regulator, 3-phosphoinositide–dependent protein kinase 1 (PDK1). By using a fluorescent probe, we monitored the conformational changes of PKB in cells using Förster resonance energy transfer detected by fluorescence lifetime imaging microscopy. Applying this approach, we show that PKB and PDK1 are found as complexes in the cytoplasm. Despite this proximity to its regulator, we show that PKB remains inactive through an intramolecular interaction of its pleckstrin homology (PH) domain and kinase domain. We refer to this inactive state as the “PH-in” conformer. Following growth factor activation, PKB changes conformation to the “PH-out” conformer and is phosphorylated by PDK1. The active “PH-out” conformer dissociates from the plasma membrane to phosphorylate downstream proteins. Our in vivo studies provide a new model for the mechanism of PKB.

1 January 2008 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
SGSebastian Guettler
Sebastian Guettler
MVMaria K. Vartiainen
Maria K. Vartiainen
FMFrancesc Miralles
Francesc Miralles
BLBanafshé Larijani
Banafshé Larijani
RTRichard Treisman
Richard Treisman
Myocardin (MC) family proteins are transcriptional coactivators for serum response factor (SRF). Each family member possesses a conserved N-terminal region containing three RPEL motifs (the "RPEL domain"). MAL/MKL1/myocardin-related transcription factor A is cytoplasmic, accumulating in the nucleus upon activation of Rho GTPase signaling, which alters interactions between G-actin and the RPEL domain. We demonstrate that MC, which is nuclear, does not shuttle through the cytoplasm and that the contrasting nucleocytoplasmic shuttling properties of MAL and MC are defined by their RPEL domains. We show that the MAL RPEL domain binds actin more avidly than that of MC and that the RPEL motif itself is an actin-binding element. RPEL1 and RPEL2 of MC bind actin weakly compared with those of MAL, while RPEL3 is of comparable and low affinity in the two proteins. Actin binding by all three motifs is required for MAL regulation. The differing behaviors of MAL and MC are specified by the RPEL1-RPEL2 unit, while RPEL3 can be exchanged between them. We propose that differential actin occupancy of multiple RPEL motifs regulates nucleocytoplasmic transport and activity of MAL.

1 December 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
FCFraser P. Coxon
Fraser P. Coxon
MHMiep H. Helfrich
Miep H. Helfrich
BLBanafshé Larijani
Banafshé Larijani
MMMariusz Muzylak
Mariusz Muzylak
JDJames E. Dunford
James E. Dunford
MRMichael J. Rogers
Michael J. Rogers
Nitrogen-containing bisphosphonate drugs inhibit bone resorption by inhibiting FPP synthase and thereby preventing the synthesis of isoprenoid lipids required for protein prenylation in bone-resorbing osteoclasts. NE10790 is a phosphonocarboxylate analogue of the potent bisphosphonate risedronate and is a weak anti-resorptive agent. Although NE10790 was a poor inhibitor of FPP synthase, it did inhibit prenylation in J774 macrophages and osteoclasts, but only of proteins of molecular mass ∼22–26 kDa, the prenylation of which was not affected by peptidomimetic inhibitors of either farnesyl transferase (FTI-277) or geranylgeranyl transferase I (GGTI-298). These 22–26-kDa proteins were shown to be geranylgeranylated by labelling J774 cells with [3H]geranylgeraniol. Furthermore, NE10790 inhibited incorporation of [14C]mevalonic acid into Rab6, but not into H-Ras or Rap1, proteins that are modified by FTase and GGTase I, respectively. These data demonstrate that NE10790 selectively prevents Rab prenylation in intact cells. In accord, NE10790 inhibited the activity of recombinant Rab GGTase in vitro, but did not affect the activity of recombinant FTase or GGTase I. NE10790 therefore appears to be the first specific inhibitor of Rab GGTase to be identified. In contrast to risedronate, NE10790 inhibited bone resorption in vitro without markedly affecting osteoclast number or the F-actin “ring” structure in polarized osteoclasts. However, NE10790 did alter osteoclast morphology, causing the formation of large intracellular vacuoles and protrusion of the basolateral membrane into large, “domed” structures that lacked microvilli. The anti-resorptive activity of NE10790 is thus likely due to disruption of Rab-dependent intracellular membrane trafficking in osteoclasts.